{"id":"dsxs-topical","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108694","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DSXS appears to be a proprietary topical delivery system developed by Sun Pharmaceutical, likely utilizing a novel formulation technology to improve skin penetration and bioavailability of its active ingredient(s). The specific molecular mechanism depends on the active pharmaceutical component, which is not publicly disclosed in available sources. As a Phase 3 topical agent, it is being evaluated for efficacy and safety in dermatological applications.","oneSentence":"DSXS is a topical formulation designed to deliver active pharmaceutical ingredients to skin lesions or dermatological conditions through enhanced penetration.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:10:03.597Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dermatological indication (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT02618759","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-08-28","conditions":"Plaque Psoriasis","enrollment":119},{"nctId":"NCT02933502","phase":"PHASE2","title":"Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-07-11","conditions":"Scalp Psoriasis","enrollment":3},{"nctId":"NCT02595073","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-09-04","conditions":"Atopic Dermatitis","enrollment":124},{"nctId":"NCT02932891","phase":"PHASE2","title":"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-08","conditions":"Atopic Dermatitis","enrollment":28},{"nctId":"NCT02595008","phase":"PHASE2","title":"Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-08-28","conditions":"Dermatitis, Atopic","enrollment":24},{"nctId":"NCT02932462","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-03","conditions":"Scalp Psoriasis","enrollment":373},{"nctId":"NCT02933866","phase":"PHASE3","title":"Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-03-11","conditions":"Scalp Psoriasis","enrollment":371},{"nctId":"NCT02933528","phase":"PHASE2","title":"Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-07-11","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT02932878","phase":"PHASE2","title":"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-09-02","conditions":"Plaque Psoriasis","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["active","Active"],"phase":"phase_3","status":"active","brandName":"DSXS topical","genericName":"DSXS topical","companyName":"Sun Pharmaceutical Industries, Inc.","companyId":"sun-pharmaceutical-industries-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DSXS is a topical formulation designed to deliver active pharmaceutical ingredients to skin lesions or dermatological conditions through enhanced penetration. Used for Dermatological indication (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}